Developer docs
API playgroundTry for free, no card

Search company profiles

Alopexx

Full company profile

uuid0009rct

Namestring
Alopexx
Legal namestring
Alopexx, Inc.
Websiteurl
alopexx.com
Company typeenum
Public
Founded yearint
2021
Operating statusenum
Ipo
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersConcord, United States
HQ citystring
Concord
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
immune therapeutics, monoclonal antibodies, antimicrobial vaccines, infectious disease biopharmaceuticals, antimicrobial resistance
Industry3 codes
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Infectious Disease Biopharmaceuticals
Social media profiles1 record
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Alopexx is a clinical-stage biotechnology company developing broad-spectrum immune therapeutics that target the conserved microbial surface polysaccharide poly-N-acetyl glucosamine (PNAG). Its two lead candidates are F598, a fully human monoclonal antibody providing immediate passive protection, and AV0328, a synthetic PNAG-conjugate vaccine delivering active immunity against bacterial, fungal, and parasitic infections including antimicrobial-resistant organisms.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Phase 1 trials completed for both F598 and AV0328 with no serious adverse events observed
+3 more records
Product overview1 text field

Alopexx is a clinical-stage biotechnology company with two distinct immune therapeutic products: a fully human monoclonal antibody (F598) and a synthetic conjugate vaccine (AV0328), both targeting the conserved PNAG antigen found on over 75 microbial pathogens. F598 provides immediate but time-limited passive protection (2-3 months) for acute settings like ICU patients, while AV0328 delivers long-term active immunity through vaccination. The PNAG Platform underlies both products and enables broad-spectrum coverage against bacterial, fungal, and parasitic infections including antibiotic-resistant organisms.

Product and service2 records
1F598 Monoclonal Antibody
CategoryMonoclonal Antibody Therapeutic
Description

A fully human IgG1 monoclonal antibody targeting PNAG (poly-N-acetyl glucosamine) that mediates killing of PNAG-expressing microbial pathogens. It provides immediate passive protection for 2-3 months from a single infusion and is being developed for prevention of healthcare-associated infections in ICU patients.

2AV0328 Vaccine
CategorySynthetic Conjugate Vaccine
Description

A synthetic PNAG-based conjugate vaccine designed to prevent infections caused by Streptococcus pneumoniae and other PNAG-expressing pathogens. Phase 1 first-in-man trial completed with demonstrated safety and broad-spectrum efficacy against over 10 microbial species, targeting serotypes and serogroups not covered by existing vaccines.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-10
Description

Collaboration with Bharat Biotech for the development and commercialization of broad-spectrum anti-microbial vaccine AV0328. This partnership leverages Bharat Biotech's expertise in vaccine development and commercialization capabilities to advance AV0328 globally, particularly in regions where affordable broad-spectrum vaccines are needed.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Moderna is a direct peer as a platform-driven vaccine biotechnology company developing mRNA-based infectious disease vaccines. Both companies pursue platform-based approaches to broad anti-infective vaccination, targeting pathogens where conventional vaccines have fallen short, and both are clinical-stage with multiple infectious disease programs.

TypeEmerging player
Description

Iterum is an emerging peer developing anti-infective therapies for drug-resistant infections. While focused on small-molecule antibiotics rather than immune therapeutics, it competes in the same AMR market opportunity that Alopexx targets with F598 and AV0328.

TypeDirect peer
Description

BioNTech is a direct peer as a platform vaccine biotech that has built infectious disease vaccine programs on a novel antigen technology (mRNA). Both companies aim to displace narrow-spectrum traditional vaccines with broad, platform-based immune approaches.

TypeBroad incumbent
Description

Merck is a broad incumbent in vaccines (Vaxneuvance pneumococcal, Gardasil) and anti-infectives. It competes with Alopexx in pneumococcal disease prevention and is a likely strategic acquirer or partner candidate for novel anti-infective platforms.

TypeBroad incumbent
Description

GSK is a broad incumbent in vaccines with extensive pneumococcal, meningococcal, and global pediatric vaccine portfolios. AV0328 competes directly with GSK's serogroup and serotype-specific franchises, particularly in meningitis and pneumonia prevention.

TypeBroad incumbent
Description

Sanofi is a broad incumbent with a leading vaccines franchise (Sanofi Pasteur) spanning influenza, pediatric combination vaccines, and emerging infectious disease targets. Sanofi is a natural strategic partner or acquirer for novel anti-infective platforms like Alopexx's.

TypeDirect peer
Description

Novavax is a direct peer as a vaccine platform biotech focused on recombinant protein nanoparticle vaccines for infectious diseases. Both companies develop novel vaccine technologies targeting infectious diseases where existing serotype- or strain-specific vaccines leave coverage gaps.

TypeEmerging player
Description

Cidara is an emerging peer developing novel immunotherapies and antivirals for serious infectious diseases. Both companies are clinical-stage biotechs pursuing immune-mediated alternatives to traditional antibiotics for prevention and treatment of resistant infections.

TypeBroad incumbent
Description

Pfizer is a broad incumbent in infectious disease vaccines, anchored by the Prevnar 13/20 pneumococcal franchise that AV0328 is positioned to complement or challenge. Pfizer is also Alopexx CBO Christine de los Reyes' former employer, illustrating the talent overlap in this space.

TypeEmerging player
Description

Arcturus is an emerging peer developing mRNA-based vaccines and therapeutics for infectious diseases. Both companies are clinical-stage platform biotechs pursuing next-generation vaccine approaches to address pathogens inadequately covered by current vaccines.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Alopexx

Infectious Disease Biopharmaceuticalsalopexx.com

Alopexx firmographics

Firmographics
Name
Alopexx
Legal name
Alopexx, Inc.
Website
https://alopexx.com
Company type
Public
Founded year
2021
Operating status
Ipo
Headcount range
11–50 employees
Ownership category
akta.pro rank

Alopexx industry classification

Industry
Product category
Infectious Disease Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)

Keywords

  • Immune therapeutics
  • Monoclonal antibodies
  • Antimicrobial vaccines
  • Infectious disease biopharmaceuticals
  • Antimicrobial resistance

Where Alopexx is headquartered

Location

Headquarters

HQ city
Concord
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Alopexx business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Distribution channels1 record

Marketing channels4 records

Alopexx product offering

Product offering

Core offering

Alopexx is a clinical-stage biotechnology company developing broad-spectrum immune therapeutics that target the conserved microbial surface polysaccharide poly-N-acetyl glucosamine (PNAG). Its two lead candidates are F598, a fully human monoclonal antibody providing immediate passive protection, and AV0328, a synthetic PNAG-conjugate vaccine delivering active immunity against bacterial, fungal, and parasitic infections including antimicrobial-resistant organisms.

Product overview

Alopexx is a clinical-stage biotechnology company with two distinct immune therapeutic products: a fully human monoclonal antibody (F598) and a synthetic conjugate vaccine (AV0328), both targeting the conserved PNAG antigen found on over 75 microbial pathogens. F598 provides immediate but time-limited passive protection (2-3 months) for acute settings like ICU patients, while AV0328 delivers long-term active immunity through vaccination. The PNAG Platform underlies both products and enables broad-spectrum coverage against bacterial, fungal, and parasitic infections including antibiotic-resistant organisms.

Differentiator

Problem solved

Functional benefit

Products and services

  • F598 Monoclonal Antibody A fully human IgG1 monoclonal antibody targeting PNAG (poly-N-acetyl glucosamine) that mediates killing of PNAG-expressing microbial pathogens. It provides immediate passive protection for 2-3 months from a single infusion and is being developed for prevention of healthcare-associated infections in ICU patients.
  • AV0328 Vaccine A synthetic PNAG-based conjugate vaccine designed to prevent infections caused by Streptococcus pneumoniae and other PNAG-expressing pathogens. Phase 1 first-in-man trial completed with demonstrated safety and broad-spectrum efficacy against over 10 microbial species, targeting serotypes and serogroups not covered by existing vaccines.

Quantifiable outcome

  • Phase 1 trials completed for both F598 and AV0328 with no serious adverse events observed
  • +3 more outcomes

Companies that use Alopexx

Customer profile

Segments4 records

Ideal customer profiles3 records

Alopexx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Alopexx partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Bharat BiotechcoreStrategic or Co-development Partner · 10 September 2024Collaboration with Bharat Biotech for the development and commercialization of broad-spectrum anti-microbial vaccine AV0328. This partnership leverages Bharat Biotech's expertise in vaccine development and commercialization capabilities to advance AV0328 globally, particularly in regions where affordable broad-spectrum vaccines are needed.

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

Alopexx competitors and assessment

Company assessment

Direct peers

  • Moderna: Moderna is a direct peer as a platform-driven vaccine biotechnology company developing mRNA-based infectious disease vaccines. Both companies pursue platform-based approaches to broad anti-infective vaccination, targeting pathogens where conventional vaccines have fallen short, and both are clinical-stage with multiple infectious disease programs.
  • BioNTech: BioNTech is a direct peer as a platform vaccine biotech that has built infectious disease vaccine programs on a novel antigen technology (mRNA). Both companies aim to displace narrow-spectrum traditional vaccines with broad, platform-based immune approaches.
  • Novavax: Novavax is a direct peer as a vaccine platform biotech focused on recombinant protein nanoparticle vaccines for infectious diseases. Both companies develop novel vaccine technologies targeting infectious diseases where existing serotype- or strain-specific vaccines leave coverage gaps.

Emerging players

  • Iterum Therapeutics: Iterum is an emerging peer developing anti-infective therapies for drug-resistant infections. While focused on small-molecule antibiotics rather than immune therapeutics, it competes in the same AMR market opportunity that Alopexx targets with F598 and AV0328.
  • Cidara Therapeutics: Cidara is an emerging peer developing novel immunotherapies and antivirals for serious infectious diseases. Both companies are clinical-stage biotechs pursuing immune-mediated alternatives to traditional antibiotics for prevention and treatment of resistant infections.
  • Arcturus Therapeutics: Arcturus is an emerging peer developing mRNA-based vaccines and therapeutics for infectious diseases. Both companies are clinical-stage platform biotechs pursuing next-generation vaccine approaches to address pathogens inadequately covered by current vaccines.

Broad incumbents

  • Merck & Co. Merck is a broad incumbent in vaccines (Vaxneuvance pneumococcal, Gardasil) and anti-infectives. It competes with Alopexx in pneumococcal disease prevention and is a likely strategic acquirer or partner candidate for novel anti-infective platforms.
  • GSK: GSK is a broad incumbent in vaccines with extensive pneumococcal, meningococcal, and global pediatric vaccine portfolios. AV0328 competes directly with GSK's serogroup and serotype-specific franchises, particularly in meningitis and pneumonia prevention.
  • Sanofi: Sanofi is a broad incumbent with a leading vaccines franchise (Sanofi Pasteur) spanning influenza, pediatric combination vaccines, and emerging infectious disease targets. Sanofi is a natural strategic partner or acquirer for novel anti-infective platforms like Alopexx's.
  • Pfizer: Pfizer is a broad incumbent in infectious disease vaccines, anchored by the Prevnar 13/20 pneumococcal franchise that AV0328 is positioned to complement or challenge. Pfizer is also Alopexx CBO Christine de los Reyes' former employer, illustrating the talent overlap in this space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Alopexx social profiles

Digital presence

Alopexx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Alopexx leadership team

Management profile

Number of profiles

Profiles5 records

Alopexx funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Alopexx M&A and investment

M&A and investment

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alopexx

What does Alopexx do?

Alopexx is a clinical-stage biotechnology company developing broad-spectrum immune therapeutics that target the conserved microbial surface polysaccharide poly-N-acetyl glucosamine (PNAG). Its two lead candidates are F598, a fully human monoclonal antibody providing immediate passive protection, and AV0328, a synthetic PNAG-conjugate vaccine delivering active immunity against bacterial, fungal, and parasitic infections including antimicrobial-resistant organisms.

Is Alopexx a public or private company?

Alopexx is a public company. It is classified as public and is currently ipo.

When was Alopexx founded?

Alopexx was founded in 2021. It employs 11 to 50 people.

Where is Alopexx based?

Alopexx is headquartered in Concord, United States, in the North America region.

Who are Alopexx's main competitors?

Direct peers on record are Moderna, BioNTech and Novavax. Emerging players are Iterum Therapeutics, Cidara Therapeutics and Arcturus Therapeutics. Broad incumbents are Merck & Co., GSK, Sanofi and Pfizer.

Does Alopexx have an API?

No public API is recorded for Alopexx.

What industry is Alopexx in?

Alopexx's product category is Infectious Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA), with a secondary code of HLAIACAM, Infectious Disease Specialty Pharmaceuticals (Non-vaccine). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American City Business JournalsAlopexx Inc. files for NYSE American IPO; Cambridge biotech seeks $30MAlopexx Inc. filed to go public on NYSE American under ticker ALPX, aiming to raise roughly $30.1 million at midpoint pricing. CEO Daniel Vlock will own 56.3% of the company after the IPO. The biotech is developing immune therapeutics for microbial infections.FierceBiotechCash-strapped Alopexx reignites plans to go public via $30M IPO to fund infectious disease programsAlopexx, a cash-strapped Cambridge, Massachusetts biotech, is planning a $30.1 million IPO on NYSE American, offering 3 million shares priced between $10 and $12 each, with the company reporting only $40,000 in remaining cash. The proceeds will fund proof-of-concept trials for two infectious disease candidates—AV0328 vaccine and F598 antibody—both targeting poly N-acetyl glucosamine (PNAG), a mechanism expressed by over 75 pathogens. F598 was previously licensed to Sanofi in 2009 under a $375 million deal but faced enrollment challenges, and CEO Daniel Vlock will hold 56.3% post-IPO, making Alopexx a "controlled company."Investing.comAlopexx files for IPO on NYSE American at $10-$12 per share By Investing.comAlopexx, Inc. has filed for an initial public offering of 3,000,000 shares of common stock on the NYSE American at an anticipated price of $11.00 per share, representing the midpoint of a $10.00 to $12.00 range. The company has applied to list under the ticker symbol ALPX, though the listing is conditional on exchange approval and the IPO will not proceed if the application is denied. Prior to this filing, there was no public market for Alopexx common stock.AInvestAlopexx - IPO price anticipated at $11 per share, range $10-$12 - SEC filingAlopexx, Inc. (ALPX), a clinical-stage biotechnology company, has filed with the SEC for an IPO on NASDAQ, seeking to price shares at $11 per share within a range of $10 to $12. The offering of 2.4 million shares plus 360,000 over-allotment could raise up to $11.6 million in gross proceeds, scheduled to price on June 25, 2026. The company is developing immune therapeutics targeting PNAG antigen and plans to use proceeds to advance proof-of-concept studies for its lead candidates AV0328 and F598.Renaissance CapitalInfectious disease biotech Alopexx nearly triples offering size ahead of $33 million IPOAlopexx, a Cambridge, MA-based infectious disease biotech developing immune therapies for bacterial, fungal, and parasitic infections, raised its IPO deal size to $33 million by offering 3 million shares at a price range of $10 to $12, nearly tripling its originally planned offering. At the midpoint of the revised terms, the company will raise 175% more in proceeds than previously anticipated, commanding a fully dilutive market cap of $102 million and becoming eligible for inclusion in Renaissance Capital's IPO statistics. The company's most advanced candidate F598 has completed Phase 1 and pilot Phase 2 trials, and Alopexx plans to list on NYSE American under the symbol ALPX, with ThinkEquity serving as sole bookrunner.BioSpaceAlopexx Announces Investment from Biotech Consortia, Inc.Alopexx, Inc. announced that Biotech Consortia, Inc. has made an investment to support the development and commercialization of its vaccine candidates, specifically AV0328. The funding aims to advance Alopexx's clinical programs for broad-spectrum immune-mediated therapeutics targeting antimicrobial resistance.PR NewswireAlopexx Vaccine Reports Successful Maternal Immunization Protecting Foals from an Intracellular Equine Pathogen Similar to TuberculosisAlopexx Vaccine LLC announced positive data for its veterinary vaccine demonstrating 91% protective efficacy in horse foals born to immunized mares, challenged with live Rhodococcus equi at approximately 4 weeks of age. The vaccine, which uses poly-N-acetyl glucosamine (PNAG)-induced antibodies, addresses a pathogen for which there are currently no licensed vaccines on the market. The results, published in PLOS Pathogens by investigators from Harvard Medical School, Brigham and Women's Hospital, and Texas A&M College of Veterinary Medicine, have supported the initiation of a Phase 1 clinical study using a fully human PNAG antibody in patients with tuberculosis.PR NewswireAlopexx Pharmaceuticals' F598 Monoclonal Antibody Binds to poly-N-acetylglucosamine (PNAG) on Microbial Surfaces Offering Potential Protective Immunity Against Multiple PathogensAlopexx Pharmaceuticals announced publication of structural data in the Journal of Biological Chemistry confirming how its F598 monoclonal antibody binds to poly-N-acetylglucosamine (PNAG), a polysaccharide found on many human pathogens including multi-drug resistant microbes. The antibody, which has completed a Phase I trial showing it was well-tolerated with a 20-30 day half-life, is in clinical development for preventing and treating serious bacterial, fungal, and protozoal infections. Alopexx obtained rights to all PNAG-targeting antibodies developed by researchers at Brigham and Women's Hospital, Harvard Medical School, and RMIT University.PR NewswireAlopexx completes first-in-man trial of its novel, broad-spectrum anti-microbial vaccineAlopexx Vaccine LLC announced completion of a Phase 1 clinical trial for AV0328, a broad-spectrum vaccine targeting the microbial antigen PNAG, in 16 healthy volunteers. The trial demonstrated the vaccine was safe and well-tolerated, with clear antibody responses at higher doses and evidence of bactericidal activity against multiple pathogens including antibiotic-resistant strains such as MRSA. The company plans to initiate a Phase 2 study in the first quarter of 2018.PR NewswireAlopexx Oncology Presents Encouraging Results Of A Phase I Study Of DI-Leu16-IL2 In Relapsed/Refractory NHL At The American Society Of Hematology Annual MeetingAlopexx Oncology presented Phase I trial data for DI-Leu16-IL2, a recombinant antibody fusion protein combining interleukin-2 with a CD20-targeting antibody, at the American Society of Hematology annual meeting in San Diego. The study enrolled 22 patients with relapsed or refractory B-cell CD20 positive lymphoma, with 15 of 18 evaluable patients showing tumor regression or stabilization, including 3 complete and 2 partial responses lasting over 12 months in many cases. The drug demonstrated favorable tolerability with mild skin rash as the most common side effect and required a 100-200-fold lower dose compared to Rituxan, suggesting potential for combination therapy with immune checkpoint inhibitors.